Bulletin of Experimental Biology and Medicine

, Volume 135, Supplement 7, pp 171–175

Comparative Efficiency of Proproten-100 during the Therapy of Patients with Alcoholism in the Stage of Therapeutic Remission

  • N. A. Bokhan
  • A. F. Abolonin
  • E. N. Krylov
  • T. P. Vetlugina
  • S. A. Ivanova
Article

Abstract

An open comparative clinical study evaluated the efficiency of Proproten-100 in reliving affective, somatovegetative, behavioral, and cognitive post-withdrawal disorders and manifestations of primary pathological alcohol addiction in patients with alcohol dependence in the stage of therapeutic remission. We compared the efficiency of Proproten-100 and standard symptomatic drugs. The preparation possessed anxiolytic, antidepressant, and vegetostabilizing properties, produced a moderate soporific effect, and had no sedative activity in patients with dysphoric depressions and psychopathic disorders. Proproten-100 was more effective during the therapy of patients with anxious and wistful depressions. Proproten-100 increased the contents of IgG and natural antibodies against S100 protein in the blood from patients. The preparation did not cause side effect or development of tolerance. Proproten-100 has psychotropic properties and holds much promise for long-term treatment of patients with alcohol dependence to reduce the incidence of recurrences.

alcohol dependence Proproten-100 antidepressant activity anxiolytic activity antibodies against S100 protein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    N. V. Aleksandrova, A. G. Gofman, E. N. Krylov, et al., Sots. Klin. Psikhiatr., 12,No. 3, 85-93 (2002).Google Scholar
  2. 2.
    Yu. V. Valentik and L. M. Savchenko, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 32-35.Google Scholar
  3. 3.
    T. P. Vetlugina, Studies of Immune Complexes in Blood Plasma from Patients with Schizophrenia. Methodical Recommendations [in Russian], Tomsk (1986).Google Scholar
  4. 4.
    A. G. Gofman, E. N. Krylov, and N. V. Aleksandrova, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, p. 103.Google Scholar
  5. 5.
    V. Ya. Semke, O. A. Vasil'eva, E. D. Krasik, et al., Immunological Tests in Patients with Schizophrenia. Methodical Recommendations [in Russian], Tomsk (1990).Google Scholar
  6. 6.
    M. B. Shtark, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 6-10.Google Scholar
  7. 7.
    O. I. Epstein, Byull. Sib. Otd. Ros. Akad. Med. Nauk, 91,No. 1, 132-148 (1999).Google Scholar
  8. 8.
    O. I. Epstein, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 11-21.Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • N. A. Bokhan
    • 1
  • A. F. Abolonin
    • 1
  • E. N. Krylov
    • 1
  • T. P. Vetlugina
    • 1
  • S. A. Ivanova
    • 1
  1. 1.Tomsk Research Center, Siberian Division of the Russian Academy of Medical SciencesInstitute of Mental HealthRussia

Personalised recommendations